Volume 25, Number 6—June 2019
Research
Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
Chad E. Mire, Joan B. Geisbert, Krystle N. Agans, Krista M. Versteeg, Daniel J. Deer, Benjamin A. Satterfield1, Karla A. Fenton, and Thomas W. Geisbert
Table 1
NiVB Serum neutralization titers in vaccinated African green monkeys (Chlorocebus aethiops)*
| Vaccine | Animal no. | Day −28† | Day 0† | Day 28† |
|---|---|---|---|---|
| None |
C-1 |
<20 |
<20 |
40‡ |
| F only vaccine | F-1 | <20 | 640 | 1,280 |
| F-2 | <20 | 160 | 2,560 | |
| F-3 |
<20 |
320 |
5,120 |
|
| G only vaccine | G-1 | <20 | 640 | 5,120 |
| G-2 | <20 | 640 | 5,120 | |
| G-3 |
<20 |
640 |
5,120 |
|
| F+G vaccine | F/G-1 | <20 | 640 | 2,560 |
| F/G-2 | <20 | 640 | 5,120 | |
| F/G-3 | <20 | 640 | 2,560 |
*Titers are reciprocal serum dilution at which 50% of virus was neutralized. NiV, Nipah virus; NiVB, NiV Bangladesh strain.
†Day postchallenge.
‡Terminal day 8 postchallenge.
1Current affiliation: Mayo Clinic, Rochester, Minnesota, USA.
Page created: May 20, 2019
Page updated: May 20, 2019
Page reviewed: May 20, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.